Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-23-023073
Filing Date
2023-05-05
Accepted
2023-05-05 07:00:14
Documents
6
Period of Report
2023-06-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20008400x2_def14a.htm DEF 14A 961975
2 ny20008400x2_pc01.jpg GRAPHIC 556073
3 ny20008400x2_pc02.jpg GRAPHIC 324270
4 ny20008400x2_pvp01.jpg GRAPHIC 128030
5 ny20008400x2_pvp02.jpg GRAPHIC 129394
6 ny20008400x2_pvp03.jpg GRAPHIC 114274
  Complete submission text file 0001140361-23-023073.txt   2686441
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-11460 | Film No.: 23891166
SIC: 2834 Pharmaceutical Preparations